What is the main topic?

The article discusses Fresenius' Q1 profit beat and its confirmed 2025 growth outlook.

How did Fresenius perform in Q1?

Fresenius exceeded profit expectations with an EBIT of 654 million euros, driven by Kabi's performance.

What are Fresenius' strategic focuses?

Fresenius is focusing on US expansion, restructuring, and growth in Kabi and Helios divisions.

Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Fresenius posts profit beat in first quarter, confirms outlook

Finance

Fresenius posts profit beat in first quarter, confirms outlook

Published by Global Banking & Finance Review®

Posted on May 7, 2025

2 min read

Last updated: January 24, 2026

Fresenius posts profit beat in first quarter, confirms outlook - Finance news and analysis from Global Banking & Finance Review

Fresenius Exceeds Q1 Profit Forecasts, Affirms 2025 Outlook

By Tristan Veyet

(Reuters) -German healthcare group Fresenius beat analysts' operating profit expectations on Wednesday, driven by a strong performance at its drug making division Kabi in the first quarter of 2025.

The company's earnings before interest and taxes (EBIT) excluding special items rose to 654 million euros ($742 million) in the quarter, compared to analysts' average estimate of 634 million euros in a poll compiled by Vara Research.

Fresenius' earnings statement echoes that of its former dialysis unit Fresenius Medical Care (FMC), which on Tuesday reported organic revenue growth across all its segments and confirmed its guidance for 2025.

The diversified healthcare group, which previously held 32.2% of FMC's shares, cut its stake to 25% plus one share in March.

Fresenius also confirmed its outlook for 2025, targeting organic revenue growth of 4% to 6% and constant currency EBIT growth of 3% to 7% for the whole group.

"With a strengthened balance sheet and capital allocation priorities to further invest in our growth platforms, while also increasing our US presence, Fresenius is well positioned to deliver future profitable growth and innovation," CEO Michael Sen said in a statement.

Fresenius joins a growing list of non-U.S. companies that are eyeing expansion in the United States in the wake of President Donald Trump's tariffs.

Following Trump's "Liberation Day" tariff announcement on April 2, Fresenius said it produced 70% of the medicines it sells in the U.S. locally.

Since taking the helm in October 2022, Sen has been revamping the organization to reduce expenditures and liabilities following a sharp drop in profits at FMC, which it has since carved out of the reporting structure.

This restructuring initiative has put Fresenius Kabi, a producer of generic hospital medications, and Helios, which operates a network of hospitals in Germany and Spain, to the forefront of Fresenius' strategy.

($1 = 0.8813 euros)

(Reporting by Tristan Veyet in Gdansk, additional reporting by Isabel Demetz, editing by Milla Nissi-Prussak)

Fresenius posts profit beat in first quarter, confirms outlook

Quick Summary

Fresenius Exceeds Q1 Profit Forecasts, Affirms 2025 Outlook

Key Takeaways

Frequently Asked Questions about Fresenius posts profit beat in first quarter, confirms outlook